Mechanisms of Glucose Lowering of Dipeptidyl Peptidase-4 Inhibitor SitagliptinWhen Used Alone orWith Metformin in Type 2 Diabetes A double-tracer study
نویسندگان
چکیده
RESEARCH DESIGN AND METHODSdWe randomized 16 patients with type 2 diabetes mellitus (T2DM) to four 6-week treatments with placebo (P), M, S, and M+S. After each period, subjects received a 6-h meal tolerance test (MTT) with [C]glucose to calculate glucose kinetics. Fasting plasma glucose (FPG), fasting plasma insulin, C-peptide (insulin secretory rate [ISR]), fasting plasma glucagon, and bioactive glucagon-like peptide (GLP-1) and gastrointestinal insulinotropic peptide (GIP) was measured.
منابع مشابه
Management of patients with type 2 diabetes and mild/moderate renal impairment: profile of linagliptin
Dipeptidyl-peptidase-IV (DPP-4) inhibitors are oral antidiabetic agents that can be administered as monotherapy in patients with contraindications to metformin or metformin intolerance, and in combination with other oral compounds and/or insulin. DPP-4 inhibitors act in a glucose-dependent manner and only increase insulin secretion and inhibit glucagon secretion under hyperglycemic conditions. ...
متن کاملDPP-4 inhibitors in the management of type 2 diabetes: a critical review of head-to-head trials.
Dipeptidyl peptidase-4 (DPP-4) inhibitors offer new options for the management of type 2 diabetes. Direct comparisons with active glucose-lowering comparators in drug-naive patients have demonstrated that DPP-4 inhibitors exert slightly less pronounced HbA(1c) reduction than metformin (with the advantage of better gastrointestinal tolerability) and similar glucose-lowering effects as with a thi...
متن کاملDPP-4 inhibitor plus SGLT-2 inhibitor as combination therapy for type 2 diabetes: from rationale to clinical aspects.
INTRODUCTION Type 2 diabetes (T2D) is a complex disease with multiple defects, which generally require a combination of several pharmacological approaches to control hyperglycemia. Combining a dipeptidyl peptidase-4 inhibitor (DPP-4i) and a sodium-glucose cotransporter type 2 inhibitor (SGT2i) appears to be an attractive approach. Area covered: An extensive literature search was performed to an...
متن کاملAddition of incretin therapy to metformin in type 2 diabetes.
Incretin-based therapies offer a new approach for the management of type 2 diabetes, with a mechanism of action distinct from any existing class of glucose-lowering agents. These drugs improve the body's ability to control blood glucose by increasing active concentrations of glucagon-like peptide-1 (GLP-1). Two approaches have been used to enhance the action of GLP-1. First, incretin mimetics (...
متن کاملCandidate Dipeptidyl Peptidase-4 Inhibitors for the Treatment of Type 2 Diabetes
Corresponding author: Dong-Lim Kim Division of Endocrinology and Metabolism, Department of Internal Medicine, Konkuk University School of Medicine, 4-12 Hwayang-dong, Gwangjin-gu, Seoul 143-729, Korea E-mail: [email protected] Type 2 diabetes mellitus (T2DM) is a progressive disease that is characterized by insulin resistance and decreased insulin secretion [1]. Based on data from the UK Prosp...
متن کامل